Growth Hormone for the Treatment of Gastroparesis
ConditionGastroparesis
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-65
SponsorMayo Clinic
About this trial
The purpose of this study is to determine whether treatment with Growth Hormone results in symptomatic improvement in patients with gastroparesis.
Eligibility criteria
Qualifiers
Symptoms > 6 months that have not responded satisfactorily to standard treatment.
For gastroparesis: Gastroparesis Cardinal Symptom Index (GCSI) score of >21
Disqualifiers
Known history of GH deficiency, hypothalamic or pituitary disease
Diabetes
Prior use of GH therapy
Age-adjusted low serum IGF1
Trial design
Treatments tested in this trial
- Growth Hormone
Treatment groups
10 Participants
are divided into 1 treatment groupLocations
2Mayo Clinic85054, PhoenixArizona, United States
Mayo Clinic in Arizona85259, ScottsdaleArizona, United States
Sponsors and collaborators
Mayo Clinic
Lead sponsor
Source ClinicalTrials.gov